Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC
Public ClinicalTrials.gov record NCT04446117. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination With Atezolizumab vs Second Novel Hormonal Therapy (NHT) in Subjects With Metastatic Castration-Resistant Prostate Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a Phase 3, multi-center, randomized, open-label, controlled study designed to evaluate the safety and efficacy of cabozantinib given in combination with atezolizumab versus a second novel hormonal therapy (NHT) in men with metastatic castration-resistant prostate cancer (mCRPC) who have previously been treated with one, and only one, NHT for their prostate cancer disease.
Study identification
- NCT ID
- NCT04446117
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 575 participants
Conditions and interventions
Interventions
- Cabozantinib Drug
- Atezolizumab Drug
- Abiraterone Acetate Drug
- Enzalutamide Drug
- Prednisone Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Male
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 19, 2020 (Actual)
- Primary completion
- Apr 19, 2024 (Actual)
- Completion
- Oct 16, 2026 (Estimated)
- Last update posted
- Dec 18, 2025
2020 – 2026
United States locations
- U.S. sites
- 36
- U.S. states
- 22
- U.S. cities
- 33
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Exelixis Clinical Site #4 | Tucson | Arizona | 85741 | — |
| Exelixis Clinical Site #42 | Duarte | California | 91010 | — |
| Exelixis Clinical Site #2 | Fullerton | California | 92835 | — |
| Exelixis Clinical Site #224 | La Jolla | California | 92093-0698 | — |
| Exelixis Clinical Site #3 | Marina del Rey | California | 90292 | — |
| Exelixis Clinical Site #114 | San Diego | California | 92161 | — |
| Exelixis Clinical Site #125 | Santa Monica | California | 90404 | — |
| Exelixis Clinical Site #245 | Stanford | California | 94305 | — |
| Exelixis Clinical Site #91 | Aurora | Colorado | 80045 | — |
| Exelixis Clinical Site #14 | Denver | Colorado | 80211 | — |
| Yale University School of Medicine | New Haven | Connecticut | 06520 | — |
| Yale University, School of Medicine | New Haven | Connecticut | 06520 | — |
| Exelixis Clinical Site #108 | Miami | Florida | 33125 | — |
| Winship Cancer Institute of Emory University | Atlanta | Georgia | 30322 | — |
| Exelixis Clinical Site #215 | Westwood | Kansas | 66205 | — |
| Exelixis Clinical Site #242 | Louisville | Kentucky | 40202 | — |
| Exelixis Clinical Site #6 | Baltimore | Maryland | 21204 | — |
| Non-participating Site | Detroit | Michigan | 48202 | — |
| Exelixis Clinical Site #203 | Rochester | Minnesota | 55905 | — |
| Exelixis Clinical Site #19 | Omaha | Nebraska | 68130 | — |
| Exelixis Clinical Site #144 | Las Vegas | Nevada | 89169 | — |
| Exelixis Clinical Site #123 | East Brunswick | New Jersey | 08816 | — |
| Non-participating Site | Lawrenceville | New Jersey | 08648 | — |
| Weill Cornell Medical College | New York | New York | 10065 | — |
| Exelixis Clinical Site #198 | The Bronx | New York | 10461 | — |
| Exelixis Site #159 | Cleveland | Ohio | 44195 | — |
| Exelixis Clinical Site #221 | Oklahoma City | Oklahoma | 73104 | — |
| Exelixis Clinical Site #18 | Philadelphia | Pennsylvania | 19111 | — |
| Exelixis Clinical Site #201 | Pittsburgh | Pennsylvania | 15232 | — |
| Exelixis Clinical Site #1 | Nashville | Tennessee | 37209 | — |
| Exelixis Clinical Site #5 | Houston | Texas | 77027 | — |
| Exelixis Clinical Site #177 | Houston | Texas | 77030 | — |
| Exelixis Clinical Site #259 | Houston | Texas | 77030 | — |
| Exelixis Clinical Site #41 | Temple | Texas | 76504 | — |
| Exelixis Clinical Site #67 | Salt Lake City | Utah | 84112 | — |
| Exelixis Clinical Site #143 | Roanoke | Virginia | 24014 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 244 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04446117, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 18, 2025 · Synced Oct 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04446117 live on ClinicalTrials.gov.